Table 1.

Summary of included studies

Study	Phase	Treatment	Number of subjects randomized/ treated	Treatment period, weeks	Insulin titration schedule
EASIE [35]	3b/4	Gla-100 + MET vs. SITA + MET	515/501	24	Twice weekly
4020 [36]	3b	Gla-100 + SU or MET vs. PIO + SU or MET	389/382	24 extended to 48	Weekly
4022 [37]	3b	Gla-100 + SU or MET vs. TZD + SU + MET	337/334	24 extended to 48	Weekly
L2T3 [38]	4	Gla-100 + OADs vs. DET + OADs	973/964	24	Every 2 days
IN-SIGHT [39]	3b	Gla-100 + current OADs vs. current OADs	405/400	24	Daily
4001 [40]	3b	Morning vs. bedtime Gla-100 + morning GLIM vs. NPH insulin bedtime + morning GLIM	700/697	24	Weekly
4013 [41]	3b	Gla-100 bedtime + morning GLIM vs. NPH insulin bedtime + morning GLIM	528/481	24	Weekly
4002 [42]	3b	Gla-100 bedtime + OADs vs. NPH insulin bedtime + OADs	764/756	24	Weekly
4014 [43]	4	Gla-100 + SU + MET vs. ROS + SU + MET	219/217	24	Weekly
4021 [44]	3b	Gla-100 + SU + MET vs. LIS 75/25 + SU + MET	212/212	24	Weekly
4041 [45]	4	Gla-100 with group education + OADs vs. Gla-100 with individual education + OADs	121/121	24	Self-titration, then investigator reviewed at each visit

DET insulin detemir, GLIM glimepiride, LIS insulin lispro, MET metformin, OAD oral antidiabetes drug, PIO pioglitazone, ROS rosiglitazone, SITA sitagliptin, SU sulfonylurea, TZD thiazolidinedione